A drug designed to halt and repair heart attack damage could change the way thousands of patients are treated, according to a research published Tuesday. The medication mimics the action of a natural rescue and repair compound, and is designed to prevent further damage to the heart, American researchers were quoted here as saying. The drug also triggers the growth of new, healthy tissue. Each year, around 120,000 people in Britain have a heart attack, where the supply of blood to the heart is suddenly blocked, usually by a blood clot. The drug was used for the first time on patients last month, in a trial that will see 80 patients taking the four-day treatment. In the most serious type of heart attack, there is a prolonged interruption to the blood supply, resulting from a total blockage of the coronary artery, which causes extensive damage and, in many cases, death, doctors said. Treatments include medication to dissolve the blood clot and restore the blood flow to the heart, and surgery to widen the coronary artery. Survival and long-term effects hinge on the amount of the muscle that dies during the attack. The smaller the area affected, the greater the chance of survival and recovery. The new drug, known as "BB3", is designed not only to stop this damage, but also to generate new heart cells. The treatment mimics the action of a naturally occurring compound that boosts the growth of heart tissue, called hepatocyte growth factor. Studies show that this compound is a crucial part of the heart's natural repair 'tool-kit' and boosts growth by encouraging the creation of blood vessels, so increasing blood supply, and also protecting existing cells from further damage. In the new clinical trial at Yale University, patients who have had a heart attack will be given the drug through an intravenous drip over four days, the British media said. Researchers say that a number of other diseases may respond to the drug approach, too. A trial for a type of stroke, where an interruption of blood flow to the brain leads to widespread damage, is also scheduled to start soon. It is thought that the drug may block the cascade of damage that destroys brain cells following a stroke. It is this expansion of the injury that leads to the devastating consequences such as paralysis. Scientists are also using this compound in heart bypass surgery, to ensure that the new vein, which is taken from the leg and grafted into the heart, implants successfully in the organ and continues to thrive after the procedure.
GMT 18:35 2018 Thursday ,11 January
Syrian refugee sets himself ablaze at UN office in LebanonGMT 18:48 2018 Tuesday ,09 January
Novo Nordisk woos Belgian nano-drug makerGMT 17:54 2017 Wednesday ,27 December
Medical evacuations begin from besieged Syria rebel bastionGMT 12:14 2017 Monday ,25 December
MoHAP successfully conducts cochlear implant operationGMT 18:24 2017 Sunday ,24 December
Palestinian conjoined twins arrive in RiyadhGMT 19:05 2017 Monday ,18 December
new! magazine names fitness & food editorGMT 17:03 2017 Wednesday ,29 November
Spain reports case of 'mad cow disease'GMT 14:05 2017 Saturday ,11 November
EU can't agree on new licence for controversial glyphosate weedkiller
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor